4th Quarter - Report

TIBER CREEK GROUP for AMGEN INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to implementation of drug pricing and reimbursement for prescription drugs provision in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D drug rebates; S. 1264 - Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —
DANIEL HOWARD ZAWITOSKI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1264 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.